The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers
- Registration Number
- NCT00612079
- Lead Sponsor
- University of Zurich
- Brief Summary
This study aims to further validate and extend our previous findings insofar that the effect of the atypical antipsychotic and mixed 5-HT2/D2 antagonist sertindole on sensorimotor gating processes and its relationship to cognitive performance shall be explored.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
- Age: 18-40
- Gender: male
Exclusion Criteria
- Axis I Disorders: lifetime DSM IV diagnosis according to DIA-X of alcohol or illicit drug dependence. No life-time DSM IV diagnosis according to DIA-X of a major affective, psychotic, anxiety disorder, eating-disorder as defined above.
- Axis II Disorders: lifetime DSM IV diagnosis of personality disorder according to SCID-II.
- Family history: lifetime history of 1st degree relative (parents and siblings) of a major affective, psychotic, or anxiety disorder as defined above.
- ECG: QTc-interval >450 msec.
- Systolic blood pressure <100 mmHg
- Bradycardia (Hf < 50/Min) und Arrhythmias
- Hypokalemia or Hypomagnesemia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 2 Placebo Healthy volunteers with high sensory gating levels. 1 Placebo Healthy volunteers with low sensory gating levels. 2 Sertindole Healthy volunteers with high sensory gating levels. 1 Sertindole Healthy volunteers with low sensory gating levels.
- Primary Outcome Measures
Name Time Method Sensory (EEG: P50 suppression) and sensorimotor gating (EMG: PPI) after placebo and and after medical treatment
- Secondary Outcome Measures
Name Time Method Cognitive performances after placebo and and after medical treatment
Trial Locations
- Locations (1)
University of Psychiatry Hospital
🇨ðŸ‡Zurich, ZH, Switzerland